C12N 2770/32734
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/32734 (Use of virus or viral component as vaccine) appears on 17 US grants and 33 published applications in this corpus.
Search patents in C12N- Granted patents
- 17
- Published applications
- 33
- Assignees
- 24
- Inventors
- 117
- Latest grant
- 22 Jun 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 2 |
| 2011 | 0 | 0 |
| 2012 | 1 | 3 |
| 2013 | 0 | 1 |
| 2014 | 2 | 2 |
| 2015 | 1 | 0 |
| 2016 | 2 | 4 |
| 2017 | 1 | 2 |
| 2018 | 3 | 2 |
| 2019 | 3 | 2 |
| 2020 | 0 | 1 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 3 |
| 2025 | 0 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Human rhinovirus vaccine22 Jun 2021US 11,040,095 B2Glaxosmithkline Biologicals SA
- Immunogenic rhinovirus peptides3 Dec 2019US 10,493,145 B2Glaxosmithkline Biologicals SA
- Rhinovirus C immunogenic peptides1 Oct 2019US 10,428,116 B2Purdue Research Foundation
- Compositions and methods for preventing and treating rhinovirus infections30 Jul 2019US 10,363,299 B2Benaroya Research Institute at Virginia Mason
- Vaccine28 Aug 2018US 10,058,603 B2Glaxosmithkline Biologicals SA
- Rhinovirus mrna vaccine7 May 2026US 2026/0124291 A1Sanofi Pasteur Limited
- Vaccine composition23 Oct 2025US 2025/0325661 A1Design-Zyme LLC
- Rhinovirus Vaccine20 Feb 2025US 2025/0057933 A1IP2Ipo Innovations Limited
- General affinity epitope polypeptide for human rhinovirus, and antibody and uses thereof24 Oct 2024US 2024/0350615 A1Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
- Methods for determining tumor immune status6 Jun 2024US 2024/0180984 A1Duke University
Most cited
By later US patents
- Equine rhinovirus 1 proteins7US 6,531,136 B1The University of Melbourne · 2003
- Immunogenic human rhinovirus (HRV) compositions4US 9,872,899 B2Biological Mimetics, Inc. · 2018
- Chimeric rhinoviruses3US 5,541,100 ARutgers University · 1996
- Rhinovirus vaccines3US 8,153,760 B2Donald Danforth Plant Science Center · 2012
- Rhinovirus C immunogenic peptides2US 10,428,116 B2Purdue Research Foundation · 2019